ANRO - Alto Neuroscience, Inc. Stock Analysis | Stock Taper
Logo

About Alto Neuroscience, Inc.

https://www.altoneuroscience.com

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.

Amit Etkin

CEO

Amit Etkin

Compensation Summary
(Year )

Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 2, 2024
Method of going public IPO
Full time employees 76

ETFs Holding This Stock

Ratings Snapshot

Rating : B-

Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 3

Most Recent Analyst Grades

Grade Summary

Buy 2
Outperform 1
Neutral 1

Showing Top 4 of 4

Price Target

Target High $16
Target Low $16
Target Median $16
Target Consensus $16

Institutional Ownership